Adjuvant immunotherapy for resected Stage III/IV (high risk) melanoma patients has been listed on the PBS. From 1 March, subsidised access to nivolumab (Opdivo) has been widened to include adjuvant treatment of completely resected stage IIIB, IIIC, IIID and stage IV malignant melanoma, regardless of BRAF mutation. The move is estimated more than 1,500 patients might ...
Immunotherapy access widened for melanoma
By Michael Woodhead
4 Mar 2020